Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Prif Awduron: V. I. Ignatyeva (Awdur), S. V. Moiseev (Awdur), N. M. Bulanov (Awdur), E. A. Karovajkina (Awdur), A S. Moiseev (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: IRBIS LLC, 2019-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...